ES3040735T3 - Prevention and treatment of atrial fibrillation/flutter with gamma-ketoaldehyde scavengers - Google Patents

Prevention and treatment of atrial fibrillation/flutter with gamma-ketoaldehyde scavengers

Info

Publication number
ES3040735T3
ES3040735T3 ES17825031T ES17825031T ES3040735T3 ES 3040735 T3 ES3040735 T3 ES 3040735T3 ES 17825031 T ES17825031 T ES 17825031T ES 17825031 T ES17825031 T ES 17825031T ES 3040735 T3 ES3040735 T3 ES 3040735T3
Authority
ES
Spain
Prior art keywords
sup
atrial
atrial fibrillation
optionally substituted
membered ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17825031T
Other languages
English (en)
Spanish (es)
Inventor
Katherine T Murray
L Jackson Ii Roberts
Venkataraman Amarnath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Application granted granted Critical
Publication of ES3040735T3 publication Critical patent/ES3040735T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
ES17825031T 2016-07-07 2017-07-07 Prevention and treatment of atrial fibrillation/flutter with gamma-ketoaldehyde scavengers Active ES3040735T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662359705P 2016-07-07 2016-07-07
PCT/US2017/041211 WO2018009875A1 (en) 2016-07-07 2017-07-07 Prevention and treatment of atrial fibrillation/flutter with gamma-ketoaldehyde scavengers

Publications (1)

Publication Number Publication Date
ES3040735T3 true ES3040735T3 (en) 2025-11-04

Family

ID=60913210

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17825031T Active ES3040735T3 (en) 2016-07-07 2017-07-07 Prevention and treatment of atrial fibrillation/flutter with gamma-ketoaldehyde scavengers

Country Status (11)

Country Link
US (2) US20190247375A1 (https=)
EP (1) EP3481505B1 (https=)
JP (1) JP7179353B2 (https=)
CN (1) CN110022936A (https=)
AU (1) AU2017293950B2 (https=)
BR (1) BR112019000251A2 (https=)
CA (1) CA3030149A1 (https=)
ES (1) ES3040735T3 (https=)
MX (1) MX393913B (https=)
PL (1) PL3481505T3 (https=)
WO (1) WO2018009875A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620836B1 (en) * 1997-01-22 2003-09-16 Jay Patrick Antiarrhythmic and tranquilizer composition and treatment
US8822542B2 (en) * 2004-10-20 2014-09-02 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
US20070249562A1 (en) 2006-04-25 2007-10-25 Friesen Albert D Treatment of atrial fibrillation
EP2477594A4 (en) * 2009-07-15 2013-03-13 Univ Vanderbilt ISOKETAL CATCHER AND TREATMENT OF DISEASES WITH OXIDATIVE INJURY
US10975033B2 (en) * 2011-07-12 2021-04-13 Vanderbilt University Methods for treating inflammation and hypertension with γ-ketoaldehyde skavengers

Also Published As

Publication number Publication date
EP3481505B1 (en) 2025-09-03
PL3481505T3 (pl) 2026-01-26
MX2019000120A (es) 2019-04-01
BR112019000251A2 (pt) 2019-04-16
AU2017293950B2 (en) 2023-06-15
JP2019520389A (ja) 2019-07-18
WO2018009875A1 (en) 2018-01-11
AU2017293950A1 (en) 2019-01-31
CA3030149A1 (en) 2018-01-11
MX393913B (es) 2025-03-24
EP3481505A1 (en) 2019-05-15
JP7179353B2 (ja) 2022-11-29
US20240189291A1 (en) 2024-06-13
EP3481505C0 (en) 2025-09-03
US20190247375A1 (en) 2019-08-15
CN110022936A (zh) 2019-07-16
EP3481505A4 (en) 2020-02-26

Similar Documents

Publication Publication Date Title
Evans et al. ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer’s disease
Sanderson et al. Molecular mechanisms of ischemia–reperfusion injury in brain: pivotal role of the mitochondrial membrane potential in reactive oxygen species generation
Han et al. Pituitary adenylate cyclase-activating polypeptide protects against β-amyloid toxicity
Godoy et al. Quercetin exerts differential neuroprotective effects against H2O2 and Aβ aggregates in hippocampal neurons: the role of mitochondria
Errico et al. Decreased levels of D-aspartate and NMDA in the prefrontal cortex and striatum of patients with schizophrenia
Shirokova et al. Cardiac phenotype of Duchenne muscular dystrophy: insights from cellular studies
Zeng et al. Neurotrophins enhance CaMKII activity and rescue amyloid-β-induced deficits in hippocampal synaptic plasticity
Domise et al. AMPK in neurodegenerative diseases
Michelucci et al. Strenuous exercise triggers a life-threatening response in mice susceptible to malignant hyperthermia
Beyreuther et al. Antinociceptive efficacy of lacosamide in rat models for tumor-and chemotherapy-induced cancer pain
Wang et al. Systemic pyruvate administration markedly reduces neuronal death and cognitive impairment in a rat model of Alzheimer's disease
Kelliny et al. A new approach to model sporadic Alzheimer’s disease by intracerebroventricular streptozotocin injection in APP/PS1 mice
Wilson et al. Mitochondrial protein S-nitrosation protects against ischemia reperfusion-induced denervation at neuromuscular junction in skeletal muscle
Ranek et al. Muscarinic 2 receptors modulate cardiac proteasome function in a protein kinase G-dependent manner
Singh et al. Role of dysregulated autophagy in HIV Tat, cocaine, and cART mediated NLRP3 activation in microglia
Lopez et al. Enhancing endogenous nitric oxide by whole body periodic acceleration elicits neuroprotective effects in dystrophic neurons
JP6928450B2 (ja) エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物及び方法
Liu et al. LRRK2 mediates α-Synuclein-induced neuroinflammation and ferroptosis through the p62-Keap1-Nrf2 pathway in Parkinson’s disease
Athari et al. AdipoRon improves mitochondrial homeostasis and protects dopaminergic neurons through activation of the AMPK signaling pathway in the 6-OHDA-lesioned rats
Palomo et al. The potential role of glycogen synthase kinase 3 inhibitors as amyotrophic lateral sclerosis pharmacological therapy
GB2571978A (en) Uses, compositions and methods
ES3040735T3 (en) Prevention and treatment of atrial fibrillation/flutter with gamma-ketoaldehyde scavengers
Lee et al. Astrocytic MAOB-GABA axis as a molecular brake on repair following spinal cord injury
HK40003085A (en) Prevention and treatment of atrial fibrillation/flutter with gamma-ketoaldehyde scavengers
HK40003085B (en) Prevention and treatment of atrial fibrillation/flutter with gamma-ketoaldehyde scavengers